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Abstract
Background: The acceptance of microarray technology in regulatory decision-making is being challenged
by the existence of various platforms and data analysis methods. A recent report (E. Marshall, Science, 306,
630–631, 2004), by extensively citing the study of Tan et al. (Nucleic Acids Res., 31, 5676–5684, 2003),
portrays a disturbingly negative picture of the cross-platform comparability, and, hence, the reliability of
microarray technology.
Results: We reanalyzed Tan's dataset and found that the intra-platform consistency was low, indicating a
problem in experimental procedures from which the dataset was generated. Furthermore, by using three
gene selection methods (i.e., p-value ranking, fold-change ranking, and Significance Analysis of Microarrays
(SAM)) on the same dataset we found that p-value ranking (the method emphasized by Tan et al.) results
in much lower cross-platform concordance compared to fold-change ranking or SAM. Therefore, the low
cross-platform concordance reported in Tan's study appears to be mainly due to a combination of low
intra-platform consistency and a poor choice of data analysis procedures, instead of inherent technical
differences among different platforms, as suggested by Tan et al. and Marshall.
Conclusion: Our results illustrate the importance of establishing calibrated RNA samples and reference
datasets to objectively assess the performance of different microarray platforms and the proficiency of
individual laboratories as well as the merits of various data analysis procedures. Thus, we are progressively
coordinating the MAQC project, a community-wide effort for microarray quality control.
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Background
The U.S. Food and Drug Administration's (U.S. FDA) Crit-
ical Path white paper (http://www.fda.gov/oc/initiatives/
criticalpath/) identifies pharmacogenomics and toxicoge-
nomics as a promising tool in advancing medical product
development and personalized medicine, and the guid-
ance for the industry on pharmacogenomic data submis-
sions has been released (http://www.fda.gov/cder/
genomics/). However, standardization is much needed
before microarrays – a core technology in pharmacoge-
nomics and toxicogenomics – can be reliably applied in
clinical practice and regulatory decision-making [1-4].
Many commercial and in-house microarray platforms are
in use, and a natural question is whether the results from
different platforms are comparable and reliable [5]. As the
U.S. FDA is actively assessing the applicability of microar-
rays as a tool in pharmacogenomic and toxicogenomic
studies, we are particularly interested in information
regarding the reliability of microarray results and the
cross-platform comparability of microarray technology.
Several studies that specifically address cross-platform
comparability report mixed results [6-15]. Receiving par-
ticular attention is the Tan et al. study [11] which com-
pares the results from three commercial platforms
(Affymetrix, Agilent, and Amersham) and finds strikingly
low cross-platform concordance, i.e., only four of the 185
unique genes identified as significantly up- or down-regu-
lated by the three platforms are in common. The results of
Tan's study are extensively cited in a recent report in Sci-
ence  [5] and quoted by other media (e.g., http://
www.nist.gov/public_affairs/techbeat/
tb2004_1110.htm#gene); they collectively portray a dis-
turbingly negative picture regarding the cross-platform
comparability and reliability of microarray technology.
The Science report [5] and the original article [11] appear
to convey the message that the observed poor cross-plat-
form concordance is largely due to inherent technical dif-
ferences among the various microarray platforms.
However, cross-platform comparability depends on intra-
platform consistency that, unfortunately, is not suffi-
ciently achieved and addressed in Tan's study [11]. As we
know, many factors affect microarray data reproducibility
and large differences in the quality of microarray data
from different laboratories using the same platform exist
[4,16]. Therefore, it is important not to confuse the poor
performance obtained in a particular study with that
achievable by the technology. We believe that appropri-
ately assessing the reliability of microarray results and the
cross-platform comparability of microarray technology is
essential towards the proper use of microarray data and
their acceptance in a regulatory setting.
Because Tan et al.'s paper [11] and the related Science
report [5] have caused a lot of confusion to the microarray
community, in this paper we set to closely re-examine the
dataset of Tan et al. to determine the exact causes of the
widely cited poor cross-platform concordance. We
describe an alternative analysis of Tan's dataset with the
intention to address several common issues related to
cross-platform comparability studies such as intra-plat-
form (technical and biological) consistency and the
impact of different gene selection and data (noise) filter-
ing procedures. We demonstrate that the main reason for
the lack of concordance among the three platforms from
Tan's study does not appear to be "because they were
measuring different things" [5], but instead appears to be
more likely because the original data [11] are of low intra-
platform consistency and analyzed with a poor choice of
methods. By analyzing the same dataset with a simple
fold-change ranking and SAM (Significance Analysis of
Microarrays) [17], we found a much higher cross-platform
concordance than Tan et al.'s original analysis suggested.
We should point out that the purpose of our work is by no
means a criticism of the study of Tan et al. In fact, the
approach by which the data were analyzed by Tan et al. is
statistically  correct and widely used in microarray data
analysis. The purpose of our work is to bring the issue on
the assessment of the merits of statistical methods to the
attention of statisticians and bioinformaticians while ana-
lyzing high-dimensional biological data such as micro-
array data [18-20]. Only after the validity of the data
analysis methods is established can the biological signifi-
cance of microarray results be reliably trusted.
Our results illustrate the need for establishing calibrated
reference RNA samples and "gold standard" datasets (e.g.,
by QRT-PCR) to objectively assess the performance of var-
ious platforms and individual microarray laboratories.
Equally importantly, the merits of various data analysis
procedures proposed for microarray data analysis must be
rigorously assessed and validated before the regulatory
utility of microarray data can be realized.
Methods
Dataset
The dataset, consisting of 2009 genes commonly tiled
across the three platforms based on matching of GenBank
accession numbers, is made publicly available by the orig-
inal authors [11][21]. Briefly, differential gene expression
in pancreatic PANC-1 cells grown in a serum-rich medium
("control" group) and 24 h following the removal of
serum ("treatment" group) is measured using three com-
mercial microarray platforms, i.e., Affymetrix (25-mer),
Agilent (cDNA), and Amersham (30-mer) [11]. RNA is
isolated from three control-treatment pairs of biological
replicates (B1, B2, and B3) of independently cultured
cells. For the first biological replicate pair (B1), the same
RNA preparations are run in triplicates on each platform,BMC Bioinformatics 2005, 6(Suppl 2):S12
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resulting in three pairs of technical replicates (T1, T2, and
T3) that only account for the variability of microarray
technology. Therefore, for the one-color platforms
(Affymetrix and Amersham), five hybridizations are con-
ducted for the control samples and five hybridizations are
done for the treatment samples. For the two-color plat-
form (Agilent), dye-swap replicates are conducted, result-
ing in a total of 10 hybridizations. More details can be
found in the original article [11].
For each platform, raw intensity data were logarithm
(base 2) transformed and then averaged for genes with
multiple representations on the microarray. The log ratio
(LR) data were calculated based on the difference in log
intensities (LI) between the two samples in a control-
treatment pair. For the Affymetrix and Amersham plat-
forms, the pairing of the control and treatment was con-
ducted in such a way that it matched the pairing on the
two-channel platform (Agilent). LR data for the dye-swap
pair were averaged for the Agilent platform.
Metrics for assessing data reproducibility
Data reproducibility was assessed according to three met-
rics, i.e., log intensity correlation (LIr2), log ratio correla-
tion (LRr2), and percentage of overlapping genes (POG),
where r2 is the squared Pearson correlation coefficient.
POG represents the number of genes common in two or
more "significant" gene lists (with consideration of regu-
lation directionality) divided by L, the number of genes in
a gene list. Unless indicated otherwise, in this study L was
set to 100 (50 up and 50 down-regulated) so that the total
number of unique genes (172) identified by our analysis
from the three platforms is close to that (185) shown in
the Venn diagram presented in the original article [11]
and the report in Science [5].
Data (noise) filtering
It has been suggested that expression data for genes
marked with "present" (or of higher intensity) appear to
be more reliable than those marked with "absent" (or of
lower intensity) [9,13,22]. Without the "absent" call
information from the dataset made available by Tan et al.,
we adopted a data filtering procedure proposed by Barc-
zak et al. [9] by excluding 50% of the genes with the lowest
average intensity across all hybridizations on each plat-
form, resulting in a subset of 537 genes (out of 2009, i.e.,
26.7%). This subset of 537 genes is presumably more reli-
ably detectable on all the three platforms, whereas data
points with lower intensity would more likely reflect plat-
form-dependent noise structures or cross-hybridization
patterns instead of real information of biological signifi-
cance. The reduced subset of 537 genes was subjected to
the same procedures for data quality assessment and gene
selection.
Gene selection methods
Three gene selection methods were applied for identifying
differentially expressed genes between the two groups of
samples: (i) fold-change ranking, (ii) p-value ranking, and
(iii) SAM [17]. For fold-change ranking, LR data were
rank-ordered and an equal number of genes (L, with each
half from the up- or down-regulation direction) were
selected from each of the platforms or replicates being
compared in order to avoid ambiguity in calculating con-
cordance. The method of fold-change ranking applies to
situations where two or more replicates (or platforms) are
being compared. However, both the p-value ranking and
SAM methods are applicable where there is a sufficient
number of replicates. In this study, both p-value ranking
and SAM were only applied to select the same number of
genes from each platform with the three biological repli-
cate pairs (B1, B2, and B3), but not for the comparison of
two replicate pairs. The p-values were calculated for each
gene using a two-tailed Student's t-test. In practice, the
ranking was performed based on the t-statistic, which car-
ries the information regarding the direction (up or down)
of regulation. Cross-platform concordance was measured
as the overlap of genes identified from different platforms.
Most discussions in this study were based on results from
fold-change ranking with a selected number of genes L =
100 (50 up and 50 down) unless otherwise indicated. Dif-
ferent numbers of genes were also selected by the three
gene selection methods.
Results
Intra-platform technical reproducibility
The intra-platform technical reproducibility can and
should be high, but appears to be low in Tan's study [11],
particularly for the Affymetrix platform. Specifically,
intensity correlation of technical replicates for the Affyme-
trix data is low compared to data from others researchers
[13,16,23] and our collaborators. A direct consequence of
low LIr2 (log intensity correlation squared) is very low
LRr2 (log ratio correlation squared): an average of 0.11
and 0.54 for before and after data filtering, respectively,
corresponding to an average POG (percentage of overlap-
ping genes) of 13% and 51% (based on the gene selection
method of fold-change ranking), respectively (Tables 1
and 2). That is, when all 2009 genes are considered, only
about 13% of the genes are expected to be in common
between any two pairs of Affymetrix technical replicates, if
100 genes (50 up and 50 down) are selected from each
replicate. In contrast, the percentage of commonly identi-
fied genes from two pairs of technical replicates is
expected to be around 51% when the analysis is limited to
the subset of 537 highly expressed genes. Figure 1 gives
typical scatter plots showing the correlation of log inten-
sity (Figures 1A and 1C) and log ratio (Figures 1B and 1D)
data from the Affymetrix platform that indicate a low
intra-platform consistency, especially before data filtering.BMC Bioinformatics 2005, 6(Suppl 2):S12
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The low intra-platform consistency is much more appar-
ent for data in the log ratio space (Figures 1B and 1D).
Since a primary purpose of a microarray gene expression
study is to detect the difference in expression levels (i.e.,
fold-change or ratio), it is important to assess data consist-
ency in the log ratio space (Figures 1B and 1D) in addition
to in the log intensity space (Figures 1A and 1C).
Technical reproducibility appears to be reasonable on the
Amersham platform: average LRr2 is 0.77 and 0.94 for the
three pairs of technical replicates before and after data fil-
tering, corresponding to a POG of 76% and 89%, respec-
tively. For the Agilent platform, technical replicate pairs
T1 and T2 appear to be very similar, but markedly differ-
ent from T3 (Figure 2A). It is notable that the Cy5 intensi-
Table 1: Data consistency for the dataset of 2009 genes (before data filtering). The pair-wise log ratio correlation squared (LRr2, lower 
triangle) and the percentage of overlapping genes (POG, upper triangle) are listed. T1, T2, and T3 are technical replicates; B1, B2, and 
B3 are biological replicates. The last three rows/columns (Affymetrix (Aff), Amersham (Ame), and Agilent (Agi)) represent results 
from the average of the three biological replicates. Gene selection was based on fold-change ranking, and a total of 100 genes (50 
genes from each regulation direction) were selected for each comparison. Black bold numbers represent intra-platform technical or 
biological consistency, or cross-platform concordance.
Aff.T1 Aff.T2 Aff.T3 Ame.T1 Ame.T2 Ame.T3 Agi.T1 Agi.T2 Agi.T3 Aff.B1 Aff.B2 Aff.B3 Ame.B1 Ame.B2 Ame.B3 Agi.B1 Agi.B2 Agi.B3 Aff Ame Agi
Aff.T1 Aff.T1 18 10 11 11 10 9 8 9 42 11 13 11 8 6 8 7 10 23 9 9
Aff.T2 0.1229 Aff.T2 11 7 9 8 5 7 6 36 19 15 9 10 9 5 6 7 23 9 8
Aff.T3 0.1112 0.0893 Aff.T3 10 7 10 11 10 11 37 12 10 9 8 7 11 9 9 22 8 12
Ame.T1 0.1548 0.1425 0.1587 Ame.T1 72 78 31 31 28 24 5 9 84 49 42 32 23 22 21 73 29
Ame.T2 0.1656 0.1701 0.1771 0.7562 Ame.T2 78 35 34 33 22 5 8 84 40 34 36 19 22 18 63 31
Ame.T3 0.1536 0.1521 0.1705 0.7821 0.7743 A m e . T 3 2 82 82 82 35 9 8 7 4 3 3 8 2 91 92 12 06 7 2 8
Agi.T1 0.1307 0.1364 0.1732 0.3176 0.3325 0.3213 Agi.T1 81 53 19 5 9 33 20 17 88 38 38 22 29 63
Agi.T2 0.1453 0.161 0.1674 0.3281 0.3499 0.3362 0.839 Agi.T2 51 19 6 8 32 21 18 86 36 38 23 30 61
Agi.T3 0.114 0.1358 0.1369 0.258 0.2867 0.2637 0.5895 0.6818 A g i . T 3 1 74 4 3 1 2 1 1 6 6 03 12 91 72 8 4 5
Aff.B1 0.5515 0.5478 0.5551 0.2755 0.3102 0.288 0.2661 0.2866 0.234 Aff.B1 16 13 25 18 16 20 17 19 40 24 21
Aff.B2 0.048 0.0877 0.0422 0.0612 0.0603 0.0664 0.0595 0.0681 0.047 0.1045 Aff.B2 14 4 7 9 5 9 9 33 6 10
Aff.B3 0.0667 0.0852 0.076 0.1191 0.111 0.1255 0.1132 0.1224 0.0856 0.1377 0.061 Aff.B3 8 6 8 9 7 9 40 9 12
Ame.B1 0.1719 0.1684 0.1836 0.9171 0.9144 0.9245 0.3525 0.368 0.2932 0.3168 0.0682 0.129 Ame.B1 48 40 34 21 23 20 73 31
Ame.B2 0.1059 0.0963 0.0801 0.5138 0.5063 0.4695 0.1445 0.1557 0.1145 0.1694 0.0754 0.0956 0.5403 Ame.B2 49 21 30 27 20 62 27
Ame.B3 0.0871 0.0835 0.0677 0.4045 0.3361 0.4771 0.1301 0.1396 0.0864 0.1431 0.0734 0.116 0.4397 0.529 A m e . B 3 1 63 03 42 05 8 2 8
Agi.B1 0.1451 0.1614 0.178 0.3364 0.3613 0.3429 0.8965 0.9314 0.8457 0.2932 0.0646 0.1189 0.3775 0.1539 0.131 Agi.B1 37 38 23 29 62
Agi.B2 0.0969 0.0883 0.0912 0.1982 0.176 0.1955 0.3946 0.4142 0.2584 0.1668 0.1263 0.103 0.2066 0.2835 0.3004 0.3926 Agi.B2 73 21 30 69
Agi.B3 0.1105 0.094 0.0984 0.1985 0.1846 0.1944 0.4178 0.4358 0.3152 0.1825 0.1251 0.1221 0.2095 0.2699 0.3055 0.4334 0.8483 A g i . B 32 4 3 37 0
Aff 0.266 0.3221 0.2698 0.2417 0.2466 0.2555 0.2324 0.2542 0.1889 0.5176 0.5015 0.6006 0.2699 0.1957 0.1976 0.2508 0.2346 0.2555 Aff 24 27
Ame 0.1522 0.1452 0.1364 0.7625 0.7245 0.78 0.2579 0.2733 0.2008 0.2616 0.0893 0.1419 0.8224 0.8208 0.771 0.2716 0.3197 0.3181 0.2772 Ame 36
Agi 0.1477 0.145 0.1552 0.3087 0.3047 0.3087 0.7209 0.7515 0.5939 0.2708 0.1204 0.1418 0.3346 0.2721 0.2744 0.7693 0.8285 0.8607 0.3045 0.3674 Agi
Table 2: Data consistency for the dataset of 537 genes (after data filtering). The pair-wise log ratio correlation squared (LRr2, lower 
triangle) and the percentage of overlapping genes (POG, upper triangle) are listed. T1, T2, and T3 are technical replicates; B1, B2, and 
B3 are biological replicates. The last three rows/columns (Affymetrix (Aff), Amersham (Ame), and Agilent (Agi)) represent results 
from the average of the three biological replicates. Gene selection was based on fold-change ranking, and a total of 100 genes (50 
genes from each regulation direction) were selected for each comparison. Black bold numbers represent intra-platform technical or 
biological consistency, or cross-platform concordance.
Aff.T1 Aff.T2 Aff.T3 Ame.T1 Ame.T2 Ame.T3 Agi.T1 Agi.T2 Agi.T3 Aff.B1 Aff.B2 Aff.B3 Ame.B1 Ame.B2 Ame.B3 Agi.B1 Agi.B2 Agi.B3 Aff Ame Agi
Aff.T1 Aff.T1 53 56 52 49 52 50 53 54 71 46 41 53 42 46 52 45 44 58 52 52
Aff.T2 0.5745 Aff.T2 44 51 53 51 48 47 46 70 46 45 53 41 41 47 43 43 61 48 47
Aff.T3 0.5902 0.4525 Aff.T3 52 51 52 53 54 53 69 37 37 53 36 39 53 38 37 48 46 47
Ame.T1 0.5341 0.53 0.572 Ame.T1 88 90 58 60 54 60 39 38 95 55 52 60 37 38 53 76 50
Ame.T2 0.5439 0.537 0.5836 0.9347 Ame.T2 89 56 58 52 59 40 39 92 57 51 58 36 36 55 77 48
Ame.T3 0.5486 0.5499 0.5768 0.9374 0.9482 A m e . T 3 5 75 95 35 94 04 0 9 4 5 5 5 4 5 83 63 75 57 8 4 8
Agi.T1 0.4382 0.446 0.5163 0.564 0.5705 0.572 Agi.T1 89 78 57 33 40 59 35 37 89 44 50 50 49 69
Agi.T2 0.4676 0.4847 0.5405 0.5954 0.6009 0.6052 0.9613 Agi.T2 84 57 38 42 62 39 39 93 49 55 53 50 75
Agi.T3 0.4553 0.4617 0.5177 0.5687 0.5729 0.5796 0.9041 0.9419 A g i . T 3 5 63 84 0 5 5 3 6 3 8 8 84 75 25 04 6 7 4
Aff.B1 0.858 0.8009 0.8076 0.664 0.6755 0.68 0.5682 0.6059 0.5822 Aff.B1 41 44 60 44 47 57 45 47 64 55 55
Aff.B2 0.4191 0.4626 0.361 0.3498 0.3524 0.3606 0.3054 0.334 0.3301 0.5029 Aff.B2 41 41 47 53 36 54 52 58 46 47
Aff.B3 0.3238 0.417 0.2726 0.3576 0.3766 0.3844 0.3515 0.3834 0.3774 0.4083 0.4451 Aff.B3 40 38 43 41 44 47 74 46 48
Ame.B1 0.5534 0.5502 0.5894 0.9767 0.9807 0.9818 0.5806 0.6129 0.5856 0.6871 0.3616 0.3806 Ame.B1 56 53 61 37 38 55 78 50
Ame.B2 0.4268 0.3686 0.3707 0.6163 0.6253 0.6093 0.313 0.3422 0.3289 0.4719 0.4917 0.2973 0.6297 Ame.B2 71 37 48 46 48 72 43
Ame.B3 0.4137 0.371 0.3575 0.579 0.5647 0.6168 0.3084 0.3389 0.3244 0.4624 0.5056 0.3427 0.5989 0.7859 A m e . B 3 3 75 55 35 27 0 5 0
Agi.B1 0.4634 0.4739 0.5363 0.5885 0.594 0.5982 0.977 0.9889 0.9686 0.5979 0.3298 0.3784 0.6059 0.3348 0.3306 Agi.B1 47 52 51 50 74
Agi.B2 0.3926 0.3393 0.3296 0.3591 0.3581 0.3627 0.4694 0.5186 0.5031 0.4293 0.5678 0.3239 0.3674 0.5783 0.5682 0.5072 Agi.B2 85 53 45 72
Agi.B3 0.3888 0.3461 0.332 0.355 0.359 0.3598 0.4975 0.541 0.5335 0.4318 0.5659 0.353 0.3654 0.5435 0.5677 0.5349 0.9525 Agi.B3 53 46 78
Aff 0.6397 0.694 0.5684 0.5686 0.5842 0.5934 0.5141 0.5563 0.5432 0.7705 0.7688 0.7978 0.5942 0.5167 0.5437 0.5491 0.5396 0.5566 Aff 58 58
Ame 0.5379 0.4995 0.5108 0.842 0.8412 0.856 0.4661 0.5019 0.4805 0.6277 0.5041 0.3921 0.8639 0.8909 0.8765 0.4931 0.5547 0.5425 0.6341 Ame 51
Agi 0.4877 0.4581 0.4759 0.5176 0.5212 0.5249 0.7747 0.816 0.7989 0.5766 0.5354 0.4123 0.532 0.5341 0.5366 0.8137 0.8863 0.9037 0.6372 0.6098 AgiBMC Bioinformatics 2005, 6(Suppl 2):S12
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ties for a subset of spots with lower intensities for one
hybridization of the dye-swap pair of T3 are significantly
different from those of T1 and T2 (data not shown). The
difference between T3 and T1 or T2 is much reduced after
data filtering (Figure 2B), largely owing to the removal of
the outlying lower intensity spots in T3. Overall, average
LRr2 on the Agilent platform is 0.70 and 0.94 for the three
pairs of technical replicates before and after data filtering,
corresponding to a POG of 62% and 84%, respectively.
It is evident from Figure 2 that intra-platform consistency
of the Affymetrix data from Tan's study is much lower
than that of the Amersham and Agilent platforms. A thor-
ough evaluation of experimental procedures would be
needed to better understand such poor performance of
the Affymetrix platform from Tan's study.
Intra-platform biological reproducibility
The intra-platform biological reproducibility appears to
be low (Figures 2A and 2B, and Tables 1 and 2) for all
three platforms. Biological replicate pairs B2 and B3
appear to be quite similar in the Agilent platform (with
LRr2 of 0.85 and 0.95, and POG of 73% and 85%, respec-
tively, for before and after data filtering). B1, however,
which is represented by the average of the three pairs of
technical replicates (T1, T2, and T3), appears to be quite
different from B2 and B3, with an average LRr2 of 0.41 and
0.52, and POG of 37% and 49%, respectively, for before
and after data filtering. The difference between B1 and B2
or B3 on the Amersham platform is also noticeable: with
average LRr2 of 0.49 and 0.61, and POG of 44% and 54%,
respectively, for before and after data filtering; whereas B2
and B3 shows a higher LRr2 of 0.53 and 0.78, and POG of
Technical reproducibility Figure 1
Technical reproducibility. A and C: The log2 intensity correlation of the control samples of technical replicate pairs T1 and 
T2 before (LIr2 = 0.84) and after (LIr2 = 0.87) data filtering, respectively; B and D: The log2 ratio correlation of the technical 
replicate pairs T1 and T2 before (LRr2 = 0.12) and after (LRr2 = 0.57) data filtering. Poor intra-platform consistency is more 
apparent in log ratios.
A
LIr2=0.84
B
LRr2=0.12
without data (noise) filtering Intensity Ratio
C
LIr2=0.87
D
LRr2=0.55
with data (noise) filtering
Intensity RatioBMC Bioinformatics 2005, 6(Suppl 2):S12
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49% and 71% for before and after data filtering, respec-
tively. Because of the low technical reproducibility of the
Affymetrix data, it is not surprising that the biological
reproducibility from the Affymetrix platform is low: with
average LRr2 of 0.10 and 0.45, and POG of 14% and 45%
for before and after data filtering, respectively (Tables 1
and 2). One possible cause of the observed low biological
reproducibility could be large experimental variations
during the processes of cell culture and/or RNA sample
preparation.
Impact of data (noise) filtering
All 2009 genes, regardless of their signal reliability, are
used in Tan's original analysis [11]. After adopting Barc-
zak et al.'s data filtering procedure [9] by excluding 50%
of the genes with the lowest average intensity on each plat-
form, a subset of 537 genes having more reliable intensity
measurement is obtained. As expected, a significant
increase in both technical and biological reproducibility is
observed (Figures 2A and 2B; notice the different scales
shown in the distance metric). The impact of data filtering
Hierarchical clustering of replicate sample pairs Figure 2
Hierarchical clustering of replicate sample pairs. Clustering was based on log ratios with average linkage and a distance 
metric of (1-LRr2), where LRr2 is the squared Pearson correlation coefficient between the log ratios. The numbers represent 
(1-LRr2), which approximately equals the percentage of uncommon genes. A: Clustering based on the expression profiles 
across 2009 genes (without data filtering); B: Clustering based on the expression profiles across 537 genes (with data filtering). 
There is a dramatic increase in LRr2 after filtering noisy data (note the different scales of the distance in each figure). Deficient 
technical and biological reproducibility on the Affymetrix platform from Tan's study [11] is evident. Technical reproducibility 
on the Agilent and Amersham platforms appears to be reasonable (B). However, although biological reproducibility can be high 
(e.g., B2 and B3 on Agilent), there appears to be a clear separation of sample B1 from samples B2 and B3.
A B
1 – LRr2 1 – LRr2BMC Bioinformatics 2005, 6(Suppl 2):S12
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on data reproducibility is more apparent from Figures 1B
and 1D when log ratios from technical replicate pairs T1
and T2 on the Affymetrix platform are compared. This
simple data filtering procedure appears justifiable for
cross-platform comparability studies, assuming that genes
tiled on a microarray represent a random sampling of all
the genes coded by a genome, and that only a (small) por-
tion of the genes coded by the genome are expected to be
expressed in a single cell type under any given biological
condition; such is the case for the PANC-1 cells investi-
gated in Tan's study [11].
Another subset consisting of 1472 genes that showed
intensity above the median on at least one platform was
subjected to the same analyses discussed for the datasets
of 2009 and 537 genes. Gene identification was also con-
ducted individually on each platform using the 50% of
genes above the median average intensity, and the con-
cordance was then compared using the three significant
gene lists. In both cases, the identified cross-platform con-
cordance was somewhere between that of the 2009-gene
and 537-gene datasets (data not shown).
Cross-platform comparability
For each platform, the LR values of the three pairs of bio-
logical replicates (B1, B2, and B3) were averaged gene-
wise and rank-ordered, and a list of 100 genes (50 up- and
down-regulated) was identified. Without data filtering, 20
genes were identified to be in common by SAM (Figure
3B). With data filtering, 51 to 58 genes were found in
common between any two platforms (Table 2), and 39
genes were in common to the three platforms, which
identified a total of 172 unique genes (Figure 3C). While
the overlap of 39 out of 172 is still low, the cross-platform
concordance is some 10-fold higher than suggested by
Tan's analysis (Figure 3A). The higher concordance
reported here is a direct consequence of the data analysis
procedure that incorporates filtering out genes of less reli-
ability, selecting genes based on fold-change ranking
rather than by a p-value cutoff, and selecting gene lists of
equal length for each platform and for each regulation
direction.
Impact of gene selection methods on cross-platform 
comparability
As increasingly advanced statistical methods have been
proposed for identifying differentially expressed genes,
the validity and reliability of the more simple and "con-
ventional" gene selection method by fold-change cutoff
have been frequently questioned [24,25]. To compare the
aforementioned results based on fold-change ranking
with more statistically "valid" methods, we also applied
SAM [17] and p-value ranking to the filtered subset of 537
genes to select 100 genes (50 up and 50 down-regulated)
from the three pairs of biological replicates on each plat-
form. For SAM, the POG between any two platforms
ranged from 48% (Amersham-Agilent) to 58% (Affyme-
trix-Agilent), and 34 genes were found in common to the
three platforms (Table 3). Of the 34 genes, 31 (91%) also
appeared in the list of 39 genes selected solely based on
fold-change ranking. Furthermore, 100 genes were also
selected from each platform solely based on p-value rank-
ing of the t-tests on the three pairs of biological replicate
pairs, and 19 of them were found in common to the three
platforms. Among the 19 genes, 11 (58%) appeared in the
list of 39 genes selected by fold-change ranking.
However, when the three gene selection methods (i.e., p-
value ranking, fold-change ranking, and SAM) were
applied to the dataset of 2009 genes to select 100 genes
from each platform (50 up and 50 down), much lower
cross-platform concordance was obtained (Table 3): only
6, 14, and 20 genes were found in common to the three
platforms by using p-value ranking, fold-change ranking,
and SAM, respectively. The results indicate the importance
of data (noise) filtering in microarray data analysis and
the larger impact of the choice of gene selection methods
on cross-platform concordance when the noise level is
higher.
It is important to note that in both cases (2009-gene data-
set and 537-gene dataset), p-value ranking yielded the
lowest cross-platform concordance (Table 3). One expla-
nation is that the p-value ranking method selected many
genes with outstanding "statistical" significance but a very
small fold change. Such a small fold change from one
platform may be by chance or due to platform-dependent
systematic noise structures (e.g., hybridization patterns).
Thus, such a small fold change is unlikely to be reliably
detectable on other platforms, leading to low cross-plat-
form concordance. For example, the gene (ID#1623)
ranked as the most significant in up-regulation from the
Affymetrix platform, exhibited a very "reproducible" log
ratio measurement for the three biological replicate pairs
(0.1620, 0.1624, and 0.1580, with a mean of 0.1608 and
standard deviation of 0.002465). The p-value of the two-
tailed Student t-test was 0.000078, representing the most
statistically significant gene from the Affymetrix platform.
However, the average log ratio of 0.1608 corresponds to a
fold change of merely 1.12 (i.e., 12% increase in mRNA
level). Such a small fold change is generally regarded as
questionable by microarray technology currently availa-
ble. On the Amersham platform, log ratios for the three
replicates were -0.3648, 0.01624, and 0.04559, with a
mean of -0.1010 (a fold change of -0.93, i.e., down-regu-
lation by 7%), standard deviation of 0.2289, and p = 0.52.
On the Agilent platform, log ratios for the three replicates
were -0.1865, 0.2698, and 0.05786, with a mean of
0.04705 (a fold change of 1.03, i.e., up-regulation by 3%),
standard deviation of 0.2283, and p = 0.75. In terms of p-BMC Bioinformatics 2005, 6(Suppl 2):S12
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value, this gene (ID#1623) was ranked as #1621 and
#1785 out of 2009 genes on the Amersham and Agilent
platforms, respectively; neither of these two platforms
selected this gene as significant. When fold-change and
SAM were applied for ranking genes based on the same
Affymetrix data, the ranking of this gene was very low
(ranked around #900 out of 2009 genes). Obviously, this
gene was not selected by fold-change ranking owing to its
small fold change (1.12).
Although fold-change ranking showed reasonable per-
formance in terms of cross-platform concordance when
applied to the subset of 537 genes, it is susceptible to
selecting genes with a large fold change and large variabil-
ity when the dataset is of low reproducibility, as is the case
for the dataset with all 2009 genes. For example, one gene
(ID#1245) was ranked as the 11th largest fold change in
up-regulation on the Affymetrix platform, but was only
ranked in the top 500 and 120 by p-value ranking and
SAM, respectively. The reason is that although this gene
exhibited an average log ratio of 2.3432 (5.07-fold up-reg-
ulation), there was a large variability in the three biologi-
cal replicate pairs (2.8986, 0.07195, and 4.0589), with a
standard deviation of 2.058 and p = 0.19. The detected log
ratios on the Amersham and Agilent platforms were
0.2955 (a fold change of 1.2273, p = 0.25) and 0.7566 (a
fold change of 1.6895, p = 0.17), respectively, leading to a
low ranking by both platforms either with fold-change
ranking or p-value ranking.
SAM ranks genes based on a modified statistic similar to t-
test: delta = u/(s+s0), where u stands for mean log ratio, s
is defined as sqrt(sd2/n), and n is the number of replicates.
By incorporating a fudge factor s0 in the denominator, in
the calculation of delta, hence the ranking of genes, SAM
effectively ranks genes relatively low in situations where
either both u and sd are small, or when u and sd are both
large [17]. Genes falling into these two situations will be
ranked high by p-value ranking and fold-change ranking,
respectively. Intuitively, SAM finds a tradeoff between
fold-change and p-value, and should be regarded as a pre-
ferred gene selection method over pure p-value ranking or
pure fold-change ranking.
It should be noted that many combinations of thorough
statistical analyses and fold-change cutoff were conducted
in Tan et al.'s original study [11]. However, the results that
were emphasized and shown in the Venn diagram [5,11]
(Figure 3A) are obtained from gene selection solely based
on a statistical significance cutoff regardless of fold-
change or signal reliability. Furthermore, because of the
use of the same statistical significance cutoff, Tan's analy-
Cross-platform concordance resulting from different data analysis procedures Figure 3
Cross-platform concordance resulting from different data analysis procedures. A: Poor cross-platform concord-
ance (4/185) is reported [11] and cited [5]; B and C: Higher cross-platform concordance was observed by our analysis of the 
same dataset. For A, the number of selected genes from each platform is determined by the same statistical cutoff (alpha = 
0.001), and the number of genes selected is 117, 77, and 34 for the Amersham, Agilent, and Affymetrix platforms, respectively. 
For B and C, the same number of genes (100) is selected from each platform by SAM (without data filtering) and fold-change 
ranking (with data filtering), respectively.
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sis resulted in an unequal number of selected genes from
the three platforms and the two regulation directions.
Therefore, the calculation of concordance becomes
ambiguous and can underestimate cross-platform con-
cordance.
Results with different numbers of genes selected as 
significant
In addition to selecting 100 genes (50 up and 50 down)
from each platform (Table 3), different numbers of genes
were selected by applying the three gene selection meth-
ods to both the 2009-gene and 537-gene datasets. The
results are shown in Figure 4 and agree with the general
conclusions discussed above when 100 genes were
selected, i.e., data filtering increased cross-platform con-
cordance and p-value ranking resulted in the lowest cross-
platform concordance. Within the same dataset, the dif-
ference in POG by different gene selection methods
diminishes as the percentage of selected genes increases.
However, the POG difference due to gene selection meth-
ods is much more significant when the percentage of
selected genes is small. The POG by p-value ranking is
consistently lower than that by fold-change ranking or
SAM. The extremely low POG when only a small percent-
age of genes are selected as significant indicates the danger
of using p-value alone as the gene selection method.
Considering the large technical and biological variations
identified in Tan's study, we conclude that the level of
cross-platform concordance with the subset of 537 genes
and by fold-change ranking or SAM is reasonable. Impor-
tantly, we observed no statistical difference between cross-
platform LRr2 and intra-platform biological LRr2 after data
filtering when all three platforms were considered (Table
2). However, it should be pointed out that the cross-plat-
form LRr2 was based on the correlation of the averaged log
ratios over the three pairs of biological replicates from
each platform as represented as Aff (Affymetrix), Ame
(Amersham), and Agi (Agilent) in the right-bottom of
Table 2.
Relationship between LRr2 and POG
From hundreds of pair-wise LRr2 versus POG comparisons
made on Tan's dataset (Tables 1 and 2), a strong positive
correlation (r2 = 0.963) between LRr2 and POG (Figure 5)
was observed. Therefore, it is essential to reach high log
ratio correlation in order to achieve high concordance in
cross-platform or intra-platform replicates comparisons.
POG by chance
It should be noted that, in addition to cross-platform
LRr2, POG also depends on the percentage P (between 0
and 1) of the total number of candidate genes selected as
"significant". As an illustration, Figure 6 shows simulated
POG results from random data of normal distribution of
N(0,1), where there is no correlation between replicates or
platforms (i.e., LRr2 = 0). For the comparison of two repli-
cates or platforms, a POG of 100*(P/2) is expected by
chance and the other 100*(P/2) is expected to be dis-con-
cordant in the directionality of regulation. For example, if
all genes (P = 100%) are "selected" as significant (50% up
and the other 50% down) for both replicates or platforms,
Table 3: Percentage of overlapping genes (POG) determined by three gene selection methods. For each gene selection method, 
different percentages of genes (P) are selected from each platform.
Percentage 
(P, %)
2009-gene Dataset 537-gene Dataset POG by 
chance
Number of 
genes
p-value Fold SAM Number of 
genes
p-value Fold SAM
3.68 74 4.0 12.2 17.6 20 0 35.0 25.0 0.034
4.98 100 6.0 14.0 20.0 27 0 34.6 34.6 0.062
7.02 141 8.6 16.4 18.6 38 8.6 36.8 31.6 0.12
9.31 187 9.1 16.7 18.8 50 10.0 36.0 34.0 0.22
9.96 200 10.0 17.0 19.0 54 9.2 35.2 33.3 0.25
14.98 301 13.2 18.9 23.2 81 16.2 41.2 33.7 0.56
18.62 374 14.4 21.9 24.1 100 19.0 39.0 34.0 0.87
19.91 400 15.2 22.5 24.7 107 24.5 36.8 35.8 0.99
30.01 603 23.6 30.6 31.4 161 27.8 45.1 43.2 2.25
37.18 747 29.4 34.0 35.2 200 34.0 51.0 48.0 3.46
39.82 800 30.7 35.1 36.6 214 36.9 52.3 50.5 3.96
55.90 1123 38.3 40.3 41.2 300 52.3 56.3 58.7 7.81
59.73 1200 39.8 41.2 41.5 321 57.2 59.4 60.6 8.92
74.51 1497 43.5 45.2 45.1 400 63.5 65.7 67.2 13.88
79.64 1600 45.4 45.6 45.7 427 66.6 67.0 65.9 15.86
100.00 2009 51.9 52.0 52.2 537 70.7 72.4 72.8 25.00BMC Bioinformatics 2005, 6(Suppl 2):S12
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by chance one would expect 50% of the total number of
selected genes to be concordant in regulation direction
(the other 50% of selected genes will be in opposite direc-
tions). For the comparison of three replicates or plat-
forms, the percentage of genes expected to be concordant
by chance is 100*(P/2)2; therefore, 25% of genes are
expected to be concordant if all genes are "selected". For
the comparison of k platforms (or replicates), the POG
expected by chance would be 100*(P/2)k-1. The POG by
chance is independent on the choice of gene selection
methods.
Discussion
We analyzed the dataset of Tan et al. [11] using an alterna-
tive approach and illustrated a number of unaddressed
issues of their study. Briefly, Tan et al.'s study suffered
from low intra-platform consistency and poor choice of
data analysis procedures. Our analysis reiterates the
importance of data quality assessment and the need for
guidelines on data analysis. The impact of data (noise) fil-
tering in microarray data analysis is shown and the prob-
lem of using p-value ranking as the only criterion for gene
selection is highlighted. For microarray studies including
cross-platform comparisons, it is essential to ensure intra-
platform consistency by using appropriate quality control
metrics and thresholds against the performance achieva-
ble on each platform.
Our data analysis procedures first involved a data (noise)
filtering procedure that excludes 50% of the genes with
the lowest average intensity on each platform. Secondly,
an equal number of differentially expressed genes were
selected from each platform, with half from up- and half
from down-regulation, in order to avoid ambiguity in the
calculation of concordance. Notice that the number of
genes identified as up- and/or down-regulated depends
on many factors such as the intrinsic nature of the biolog-
ical samples, the number of gene probes present on the
platform, the reproducibility (precision) of the platform,
and the cutoff value of significance level. Therefore, the
number of genes to be identified from each platform in a
given study could be arbitrary, but in practice is limited by
the number of genes that the biologist is interested in or is
capable of examining in greater detail. It should be noted
that for platforms with different reproducibility, the p-
value or false discovery rate (FDR) cutoff will most likely
be different when the same number of genes are selected
based on fold-change ranking. However, for dataset of
reasonable consistency, most genes selected by fold-
change ranking also pass a p-value cutoff. Alternatively,
when the same statistical cutoff (e.g., a p-value < 0.001) is
applied to different platforms, a platform that demon-
strates higher consistency will select more genes than that
POG at different percentages of genes selected as significant  with three gene selection methods Figure 4
POG at different percentages of genes selected as 
significant with three gene selection methods. In both 
cases (with or without data filtering), p-value ranking resulted 
in much lower cross-platform concordance compared to 
fold-change and SAM, in particular when a small percentage 
(e.g., <20%) of candidate genes are selected as significant, 
suggesting that the most significant genes selected by p-value 
ranking from one platform are unlikely to be selected as sig-
nificant from another platform. POG by chance (assuming no 
correlation in log ratios, i.e., LRr2 = 0 among the three plat-
forms) is also shown. See Figure 6 for more information on 
POG by chance.
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Relationship between LRr2 and POG Figure 5
Relationship between LRr2 and POG. The squared 
pair-wise log ratio correlation (LRr2) and the percentage of 
overlapping genes (POG) showed a strong correlation (POG 
= 0.223 + 94.425* LRr2, r2 = 0.963, N = 462). Each data point 
represents an LRr2 ~ POG pair from Tables 1 and 2.
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with lower consistency, as shown in Figure 3A. Thirdly, we
compared three different gene selection methods (p-value
ranking, fold-change ranking, and SAM) and compared
the cross-platform concordance. The results illustrate the
danger of solely using p-value ranking in gene selection
without considering fold change. On the other hand, fold-
change ranking appears to perform well in identifying
gene lists with large cross-platform overlap, which is a rea-
sonable surrogate for assessing the accuracy of microarray
data [14]. The most reliable results should be those genes
showing low p-value and large fold change.
Overall, based on the same dataset of Tan et al., our rean-
alysis gives a cross-platform concordance (39 out of 172)
some 10-fold higher than reported by the original authors
[11] and extensively cited in Science [5], where only 4 out
of 185 genes are found in common. Due to the limited
quality of the dataset of Tan et al., it is reasonable to expect
a higher cross-platform concordance when the quality of
data from each platform increases to the best achievable
levels. Reasonable cross-platform concordance can and
should be attainable if microarray experiments are con-
ducted at the level of performance achievable by the tech-
nology and if the resulting data are analyzed with
validated methods.
It should be noted that POG depends on the percentage
(P) of genes selected out of the candidates; the higher per-
centage selected the higher the POG (Figure 4). When the
results identified from the dataset of 2009 genes were
compared to those from the subset of 537 genes, the
results were based on the selection of the same number of
100 genes (50 up and 50 down) from each platform, cor-
responding to 4.98% and 18.62%, respectively, out of the
total numbers of the candidate genes. The corresponding
percentages of concordant genes by chance for the com-
parison of any two platforms are 2.49% and 9.31%. For
the comparison of three platforms, the corresponding per-
centages of overlap by chance are approximately 0.25%
and 0.87% for the 2009-gene dataset and 537-gene sub-
set, respectively. Therefore, such a bias of POG towards a
higher percentage of selected genes should be kept in
mind when reading the numbers from comparing the two
datasets, especially when two platforms are compared.
Increasingly complicated statistical methods have been
continually proposed for identifying differentially
expressed genes, and the validity and reliability of the sim-
ple gene selection method by fold-change ranking (cutoff)
have been questioned [24,25]. The preference of using a
statistical significance metric (e.g., p-value) as the gene
selection method [25] is biased to random noise and plat-
form-dependent systematic errors, resulting in the selec-
tion of genes with tiny fold changes that are indiscernible
by currently available microarray technology. The fact that
fold-change ranking identified a much higher percentage
of concordant genes among the three platforms than p-
value ranking is not difficult to understand when we con-
sider microarray as a measurement tool and its fluores-
cence intensity detection is subject to various sources of
variability. Therefore, only those fold changes that are
above random intensity variation are reliable.
Multi-factorial nature of cross-platform concordance
One of the goals of gene expression studies is to reliably
identify a subset of genes that are differentially expressed
in two different types of samples. Our results (Figure 5)
demonstrate that it is essential to reach high log ratio cor-
relation (LRr2) between two replicates or platforms in
order to achieve high consistency between the lists of
identified genes. There are several ways to increase LRr2
and the most important steps should be setting quality
control checkpoints to make sure that experimental varia-
bility is kept as small as possible so that, in turn, data from
the same platform are reliable. After data collection, a rea-
sonable data (noise) filtering procedure should be
applied to exclude a portion of genes with the lowest
intensity that likely reflects platform-specific noise struc-
tures (e.g., cross-hybridization patterns). Increasing the
number of replicates is theoretically important, but in
practice is limited by the available resources. It is worth
POG by chance Figure 6
POG by chance. The percentage of overlapping genes 
(POG) increases by chance when the percentage (P) of 
selected genes (out of candidate genes) increases. For k rep-
licates or platforms compared, the log ratios of the simulated 
replicates or platforms are assumed to have a normal distri-
bution of N(0,1) and no correlation between each other 
(LRr2 = 0). The expected POG by chance is 100*(P/2)k-1, 
where k is the number of replicates or platforms. POG2, 
POG3, POG4, and POG5 correspond to the comparison of 
2, 3, 4, and 5 replicates (or platforms), respectively.
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noting that the log ratio correlation of replicates largely
depends on the magnitude of true biological differences
in expression levels between the two groups of samples
compared. For the comparison of dramatically different
types of samples (e.g., two different types of tissues or cell
lines), the expected fold change for many genes is large,
resulting in reproducibly measurable fold change for
many genes. On the other hand, when the inherent bio-
logical differences between the two groups of samples are
small (e.g., control animals versus animals chronically
treated with a chemical in low-dose, or two truly different
cell populations that are "diluted" with common,
unchanged, larger cell populations as seen in neurotoxico-
logical studies), the reproducibility of the measured fold
change is expected to be lower. For the detection of such
subtle changes in gene expression, it is essential to opti-
mize microarray protocols to obtain the best performance
that is achievable.
Inherent differences among various platforms
Our analysis amplifies the need for appropriate metrics
and thresholds to objectively assess the quality of micro-
array data prior to devoting effort to more advanced statis-
tical analysis. Our work also reiterates the urgent need for
guidance on consistency in analyzing microarray data
[4,26,27]. We agree that inherent technical differences
among various microarray platforms exist because of dif-
ferences such as probe length and design, patterns of
cross-hybridization and noise structures, as well as exper-
imental protocols. For example, the intra-platform con-
sistency for the Amersham and Agilent platforms is
significantly higher, but the concordance between these
two platforms was not higher than the cross-platform con-
cordance involving the Affymetrix platform (Figure 3B),
which showed the lowest intra-platform consistency. In
addition, as shown in Table 2, the three technical replicate
pairs (T1, T2, and T3) on both Agilent and Amersham
platforms showed the same average LRr2 of 0.94 and an
average POG of 84% (Agilent) and 89% (Amersham), but
the cross-platform LRr2 (between Agi.B1 and Ame.B1) was
only 0.60, corresponding to a POG of 61%. Such a differ-
ence (LRr2 of 0.94 versus 0.60, and POG of 84%/89% ver-
sus 61%) could be a result of inherent platform
differences, e.g., cross-hybridization patterns due to differ-
ences in probes (cDNA versus 30-mer), and differences in
detection methods (two-channel versus one-channel).
The "true" cross-platform differences, e.g., whether the
probes from different platforms supposedly measuring
the same gene are in fact targeting different regions or
splicing variants of the same gene [13,28], should be
resolved with more reliable datasets. The lack of gene
identity information from the dataset made public by Tan
et al. prevented us from using probe sequence matching to
determine gene overlap across different platforms [28]
and to assess the degree of improvement of cross-platform
concordance.
Calibrated reference RNA samples and "gold standard" 
datasets
Because the U.S. FDA is expected to receive microarray-
based pharmacogenomic data as part of product submis-
sions from the industry, data quality is of great concern.
Although cross-platform concordance is important, what
is more important is the accuracy of each platform. How-
ever, the accuracy of microarray technology has not been
extensively assessed due to the lack of calibrated reference
RNA samples and "gold standard" measurements. We are
coordinating the MAQC (Microarray Quality Control)
project [29] (http://www.gene-chips.com/MAQC/ or
http://edkb.fda.gov/MAQC/) aimed at assessing the per-
formance achievable on various microarray platforms
through a collaborative effort among six FDA Centers, the
National Institute of Standards and Technology (NIST),
the U.S. Environmental Protection Agency (EPA), major
microarray platform providers (e.g., Affymetrix, Agilent,
Applied Biosystems, GE Healthcare and Illumina), RNA
sample providers (e.g., Ambion, Clontech and Strata-
gene), selected microarray users (e.g., NCI, UCLA and
UMass), and other stakeholders. Reference datasets will
be generated on a pair of readily accessible RNA samples
for each species (human, mouse, and rat) by multiple lab-
oratories using multiple platforms, and will be made pub-
licly available for objective assessment of intra-platform
consistency, cross-platform comparability, and the com-
parison of various data analysis methods. Importantly,
the relative expression levels for over one thousand genes
in these samples will be measured by QRT-PCR and other
independent technologies. The resulting "gold standard"
datasets will be used to assess the accuracy of various
microarray platforms. We expect that the "calibrated" ref-
erence RNA samples, reference datasets, and the resulting
quality control metrics and thresholds will facilitate regu-
latory review of genomic datasets. Individual microarray
laboratories can optimize and standardize their SOPs by
using the same pair of RNA samples and checking their
data quality against the reference datasets. By using these
tools, a procedural failure may be identified and cor-
rected, and the intrinsic technical differences among plat-
forms can be better understood and addressed. The
MAQC project, which is highly complementary to on-
going efforts of the External RNA Controls Consortium
(ERCC, http://www.cstl.nist.gov/biotech/workshops/
ERCC2003/) and NIST's Metrology for Gene Expression
Program (http://www.nist.gov/public_affairs/techbeat/
tb2004_1110.htm#gene), will help move the process of
standardizing microarray technology one step further.BMC Bioinformatics 2005, 6(Suppl 2):S12
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Quality control metrics and thresholds
Quality control metrics (parameters) need to be estab-
lished for assessing the quality of microarray data. Equally
important, thresholds for the quality control parameters
should be established to determine whether the data qual-
ity from a study is acceptable. Before any advanced statis-
tical analysis, exploratory analysis of microarray data in
terms of the quality metrics (e.g., LIr2, LRr2, and POG)
may be used to identify irregularities in the data. The ref-
erence RNA samples and the reference datasets mentioned
above will be essential to determine quality control
thresholds.
The need of guidance for microarray data analysis
Guidance on data analysis is needed in the standardiza-
tion of microarray technology. A significant portion of the
more than 10000 literature references on microarrays
[4,18] deals with various strategies on data analysis. How-
ever, many of the methods or procedures have not been
independently validated for their merits and limitations
[18,30]. It is expected that reference datasets will enable a
more reliable assessment of the merits of various proce-
dures and methods for microarray data analysis. It is
important not to compromise accuracy for the sake of
reproducibility in microarray data analysis [31]. Unfortu-
nately, many methods (e.g., p-value or FDR cutoff) cur-
rently used in microarray data analysis appear to focus on
reproducibility because of the lack of independent data-
sets for cross-validation. With the availability of "gold
standard" measurements and cross-platform datasets
from the calibrated reference RNA samples, it is possible
to judge the performance of individual data analysis
methods against the "true" values, not against themselves
(i.e., data from the same platform in the same study).
We realize that the absence of control (comparison) data,
e.g. from QRT-PCR analysis, limits the conclusions that
can be drawn from Tan's dataset. Ultimately, it is the accu-
racy of the platform that determines its usefulness in
research. It is also possible that different data analyses
need to be used for specific platforms. As already indi-
cated in the "note added in proof" of Tan et al. [11], a
comparison between the Affymetrix platform and a long-
oligo platform have revealed high concordance when
used with identical RNA preparations [9]. However,
before QRT-PCR data become available for a large subset
of genes for the same pair of reference RNA samples, we
suggest the use of cross-platform concordance as a surro-
gate of accuracy in order to evaluate the performance of
different data analysis methods. Preliminary results illus-
trated in this paper indicate the limitations of p-value
ranking (or p-value cutoff) when used alone as the gene
selection method. The reliability of gene selection based
on fold-change ranking has been demonstrated for data-
sets of higher quality when compared to the results from
more sophisticated SAM method.
Conclusion
Our reanalysis of the dataset of Tan et al. [11] illustrates
two paramount challenges facing the microarray commu-
nity. The first challenge is to ensure that individual micro-
array laboratories perform the bench work in a proficiency
that is achievable by the technology. The second challenge
is to critically evaluate and validate the merits of various
data analysis methods (procedures). Currently, there is a
lack of appropriate tools for microarray users to objec-
tively assess the performance of microarray laboratories.
In addition, as a community, we are not in short of
"novel" methods for analyzing microarray data; on the
contrary, the user is being faced with too many options
and the true merits of such methods (procedures) have
not been adequately evaluated. The outcomes of the
ERCC and MAQC efforts will greatly help address the two
challenges facing the microarray community, leading to
more reliable, wider applications of the microarray tech-
nology.
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